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ABSTRACT

Apoptosis is essential for cellular homeostasis and is also a pathologic feature of various
diseases. The balance between Bcl-2 family proteins determines whether a cell will live or die.
Bax, a member of the BCL-2 family proteins, is a pro-apoptotic protein that exists in both a
soluble, cytoplasmic form and a membrane-bound form. Upon apoptotic stimuli, Bax undergoes
a conformational change and translocates to the mitochondria, initiating apoptotic events.
However, little is known about whether Bax is involved in the regulation of mitochondrial
function under non-apoptotic conditions, and how Bax binds to mitochondria to exert its activity.
Here, we investigate the role of Bax in the regulation of mitochondrial function under nonapoptotic conditions and explore the molecular mechanisms for Bax binding mitochondria under
apoptotic stimuli.
Using Bax-containing and Bax-deficient (Bax-/-) HCT-116 cells, we examined Bax
cellular localization and its effects on mitochondria bioenergetics, and also tested whether overexpression of full-length Bax in Bax-/- cells would recover mitochondrial metabolic activity. To
determine the effects of Bax localization upon mitochondrial function, we measured citrate
synthase activity and ATP generation. We showed that Bax localized to the outer and inner
mitochondrial membranes in non-apoptotic cells, enabling the activity of citrate synthase and the
generation of ATP. Loss of Bax led to impairment of respiring mitochondria morphology and
reduced oxidative capacity, all of which was restored by expression of full-length or C-terminaldeleted Bax.

These findings indicate that under non-apoptotic conditions, the constitutive

expression of Bax is necessary for mitochondrial bioenergetics.
iii

To determine the molecular mechanisms for Bax binding mitochondria under apoptotic
stimuli, we previously performed in silico-mutagenesis and predicted that Lysines 189/190, in
the C-terminal α9 helix, could regulate Bax binding to mitochondria. We demonstrated here that
these lysines are the structural elements responsible for controlling how Bax interacts with the
mitochondrial membrane. Expression of full-length Bax led to mitochondrial translocation and
apoptosis, whereas deletion of the α9 helix resulted in cytosolic retention and dramatically
reduced cell death.

Mutation of the two lysine residues changed how Bax bound to

mitochondrial membranes. We replicated the results achieved with full-length Bax by attaching
the α9 helix of Bax to GFP or to a regulatory element, the degradation domain (DD), and
induced apoptosis upon expression in cells. We demonstrated that the α9 helix alone promoted
the mitochondrial translocation of Bax and increased apoptosis. These results indicate that the
C-terminal α9 helix could be further studied for use in cancer therapies.
Overall, we have demonstrated that the constitutive expression of the inactive form of
Bax in non-apoptotic cells is necessary for mitochondrial bioenergetics, and have identified the
C-terminal α9 helix of Bax as the effector domain of apoptotic function.

iv

ACKNOWLEDGMENTS

“Life is but a dream”. This children’s song packed with many meaning and inspiration to me.
Doing this research project actualize one of my dreams.
I am heartily thankful to my advisor, Dr. Annette Khaled, who let me to realize my passion, full
potential, true nature and to develop an understanding of the subject. This thesis would not have
been possible without her encouragement, guidance and support from the very beginning to the
end. It is a pleasure to thank my committee members Dr. Deborah A. Altomare and Dr. Zixi
Cheng without their support this project would not have been quickly successful. I would like to
thank Dr. Henry Daniell for his advice whenever I need. Special thanks also to all my lab mates,
Dr. Kathleen Nemec, Rebecca Boohaker, Nuska Tschammer, Adina Loosley Carlson, Shannon
Ruppert, Dr. Christina Kittipatarin, Dr. Mounir Chehtane for sharing the literature, abundantly
helpful and invaluable assistance.
Lastly, deepest love and gratitude to my beloved families, my son Evan and my husband Jianli,
for their understanding and endless love, they always been there during this journey.

v

TABLE OF CONTENTS

LIST OF FIGURES ....................................................................................................................... ix
CHAPTER 1: GENERAL INTRODUCTION ............................................................................... 1
CHAPTER 2:

BAX SUPPORTS THE MITOCHONDRIAL NETWORK, PROMOTING

BIOENERGETICS IN NON-APOPTOTIC CELLS ...................................................................... 6
Introduction ................................................................................................................................. 6
Materials and Methods ................................................................................................................ 7
Cell Lines and Reagents .......................................................................................................... 7
Plasmids, Mutagenesis, and Transfection................................................................................ 7
Measurement of Oxygen Consumption and Extracellular Acidification Rates ...................... 8
Mitochondrial Staining, Fixed- and Live-Cell Imaging .......................................................... 9
Sub-cellular Fractionation and Immunoblots .......................................................................... 9
Proteinase K Digestion of Membrane Bound Proteins .......................................................... 10
Measurement of ATP production and Mitochondrial Membrane Potential .......................... 11
Measurement of Citrate Synthase Activity............................................................................ 12
Measurement of Mitochondrial DNA.................................................................................... 12
Statistics ................................................................................................................................. 13
Results ....................................................................................................................................... 13
vi

Bax is essential in mitochondrial bioenergetics .................................................................... 13
Bax associates with mitochondria and contributes to ATP production ................................. 16
Expression of full-length Bax restores mitochondrial metabolic activity in Bax-/- cells ....... 18
Discussion ................................................................................................................................. 27
CHAPTER 3: THE C-TERMINAL α9-HELIX OF BAX IS THE EFFECTOR DOMAIN OF
APOPTOTIC FUNCTION ........................................................................................................... 31
Introduction ............................................................................................................................... 31
Materials and Methods .............................................................................................................. 32
Cell lines and Reagents.......................................................................................................... 32
Plasmids, Mutagenesis and Transfection............................................................................... 33
Mitochondrial Translocation Assay and Immunoblotting ..................................................... 34
Fixed- and Live-Cell Imaging ............................................................................................... 35
Statistical Analysis ................................................................................................................ 37
Results ....................................................................................................................................... 38
The C-terminal α9 helix is critical for Bax intracellular localization and apoptotic activity 38
The C- terminus Lys 189/190 of Bax is involved in Bax binding to mitochondria .............. 39
The C- terminus Lys 189/190 of Bax is critical for Bax apoptotic activity .......................... 40
Expression of the C-terminal α9 helix of Bax induces the translocation of Bax to
mitochondria .......................................................................................................................... 40

vii

Expression of the C-terminal α9 helix of Bax induces apoptotic cell death ......................... 41
Expression of the C-terminal of Bax on ATP production in HCT-116 cells ........................ 43
Discussion ................................................................................................................................. 56
CHAPTER 4: CONCLUSIONS ................................................................................................... 60
REFERENCES ............................................................................................................................. 62

viii

LIST OF FIGURES

Figure 1. Loss of Bax leads to altered respiring mitochondria morphology. ............................... 20
Figure 2. Loss of Bax leads to reduced mitochondrial oxidative capacity. .................................. 22
Figure 3. Bax associates with mitochondria in non-apoptotic cells resulting in reduced citrate
synthesis activity. .......................................................................................................................... 23
Figure 4. Expression of full-Length Bax restores mitochondrial association and ATP production
in Bax-/- cells. ................................................................................................................................ 25
Figure 5. Mutation of Lys 189/190 at C-terminal of Bax alters intracellular localization. .......... 44
Figure 6. Mutation of Lys 189/190 at C-terminus of Bax alters apoptotic activity of Bax. ........ 45
Figure 7. EGFP tagged C- terminus Lys 189/190 mutation of Bax alters intracellular localization.
....................................................................................................................................................... 46
Figure 8. GFP tagged C-terminal peptide of Bax, but not mutant peptides, induced cell death in
HCT-116 cells. .............................................................................................................................. 47
Figure 9. Intracellular localization of DD-tagged full-length and DD-tagged C-terminus Lys
189/190 mutants. ........................................................................................................................... 48
Figure 10. Detection of intracellular localization of DD-tagged C-terminus Lys 189/190 mutants
by immunofluorescent staining. .................................................................................................... 49
Figure 11. Expression of DD-tagged Bax C-terminal peptides induced cell death in HCT-116
cells. .............................................................................................................................................. 50
Figure 12. Detection of cell death by flow cytometry. ................................................................. 51

ix

Figure 13. Expression of C-terminal Bax on ATP production in Bax+/+and Bax-/- HCT-116 cells.
....................................................................................................................................................... 52

x

LIST OF ACRONYMS/ABBREVATIONS
AIF: Apoptosis inducing factor
ANT: Adenosine nucleotide translocator
Bax: BCL-2 associated protein
BCL-2: B-cell lymphoma 2 protein
BH: BCL-2 homology
BSA: Bovine serum albumin
DD: Degradation domain
DMSO: Dimethyl sulfoxide
DNA: Deoxyribonucleic acid
dsRNA: Double stranded RNA
ECAR: Extracellular acidification rate
EGFP: Enhanced green fluorescent protein
ER: Endoplasmic reticulum
FACS: Fluorescence-activated cell sorter
FBS: Fetal bovine serum
FCCP: Carbonylcyanide-p-trifluoro-methoxyphenylhydrazone
HA: Hemaglutinin
HRP: Horseradish peroxidase
HSP60: Heat shock protein 60
IMM: Inner mitochondrial membrane
IMS: Intermembrane space

xi

IRES: Internal ribosome entry site
NAO: 10-Nonyl Acridine Orange
OCR: Oxygen consumption rate
OMM: Outer mitochondrial membrane
PBS: Phosphate Buffer Solution
PCR: Polymer chain reaction
PTT: Proteo Tuner plasmid
PVDF: Polyvinylidene difluoride
RNA: Ribonucleic acid
SD: Standard deviation
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis
3D: Three dimensional
VDAC: Voltage-dependent anion channel
WT: Wild type

xii

CHAPTER 1: GENERAL INTRODUCTION

“Life is pleasant, death is peaceful. It‟s the transition that„s troublesome.” Isaac Asimov
Apoptosis is a cell death program that is critical for cellular and tissue homeostasis and is
also a key pathologic feature of various diseases. Over the past decade, the role of mitochondria
has been increasingly recognized as an important mediator for the apoptotic process, and release
of mitochondria apoptotic factors is considered as the “point of no return” in apoptotic signaling
[1-3].

Upon an apoptotic stress signal, the permeabilization of the outer mitochondrial

membrane (OMM) allows the release of cytochrome c and other apoptotic proteins from the
intermembrane space of mitochondria, leading to the activation of the caspase cascade and
apoptotic cell death [2,3]. This process is in part regulated by the Bcl-2 family of proteins,
which can be classified into three groups based on their structure and their role in apoptosis: (1)
the pro-apoptotic proteins, such as Bax and Bak, which contain three Bcl-2 homology (BH)
domains BH1, BH2, and BH3; (2) the anti-apoptotic proteins like Bcl-2, Bcl-XL, Bcl-w and Mcl1, which contain four homology domains BH1, BH2, BH3 and BH4; and (3) the BH3-only
proteins such as Bid, Bim and Bad, which induce apoptosis by either activating pro-apoptotic
proteins like Bax or by suppressing anti-apoptotic proteins like Bcl-2. Most of these proteins
share one to four BH-domains and contain a C-terminal hydrophobic α-helix that is involved in
their localization to either the OMM or endoplasmic reticulum (ER) membranes [4-7]. Bax
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participates in the induction of apoptosis in response to a variety of stimuli, and Bax
conformational changes and translocation into the OMM is recognized as a key event triggering
mitochondria-dependent apoptosis [1, 3, 7].
Bax is a 21 KD pro-apoptotic protein of 192 amino acids comprising 9 alpha helices [8].
The hydrophobic α5-α6 hairpin helix is located in the central core surrounded by 7 amphipathic
α-helices. NMR data on the 3-D structure of Bax shows that alpha helix 9 is situated within a
hydrophobic groove. Generally, the localization of Bax is cytosolic in most healthy cells,
although some mitochondria localization has been described [Putcha et al., 1999, 2002;
Kaufmann et al., 2004]. Many functions of Bax can be attributed to specific domains. The BH3
domain is mostly found in the alpha 2 helix and has been shown to be involved in the heterodimerization with other Bcl-2 family proteins [9-11]. The hydrophobic helix 9 and helices 5/6
has been implicated in the activation, self-association and mitochondria membrane binding of
Bax [11-14].
The translocation of Bax from the cytosol to the OMM is a critical event in apoptosis.
Although the precise mechanism remains to be elucidated, two models of Bax activation have
been proposed to explain the activation of Bax during apoptosis [7, 15]. Briefly, in the first
model, upon apoptotic stimuli the BH3-only Bcl-2 family proteins interact with Bax, leading to
conformational changes that result in the formation of oligomers and insertion into the OMM. In
the second model, the conformational changes of Bax occurs in the cytosol leading to release of
the C-terminal α9 helix from the hydrophobic grove, thereby exposing the previously hidden
BH3 domain. Bax then inserts into the OMM either through its N-terminus [14,16,17] or its Cterminus [18-20].

Studies from our group and others showed that pH could induce a
2

conformational change in Bax, resulting in the C-terminal and BH3 domain being exposed,
leading to mitochondria translocation [21, 22]. Others have shown that Bax can insert into
membranes as a monomer, suggesting that the insertion step occurs prior to oligomerization [23].
How Bax translocates to the OMM is still a matter of debate.
Recently, it was suggested that Bax C-terminus is required for Bax translocation to
mitochondrial during apoptosis [18-20]. Some reports suggest that the C-terminal anchor is not
required for Bax translocation during apoptosis [14, 25]. Deletion of the C-terminal 22 amino
acids failed to block recruitment of Bax to mitochondria during apoptosis [22]. While others
studies showed that the C-terminus is needed to translocate Bax to mitochondria. As example,
mutating proline 168, upstream of the C-terminus prevented Bax translocation during apoptosis
and abolished its apoptotic activity (16, 19, 20). Despite these findings, whether the C-terminus
of Bax is a membrane binding domain or a regulatory domain remains to be analyzed. We
performed computational-mutagenesis studies to determine the potential amino acids of the Cterminus necessary for Bax membrane binding activity. Based on the differences in helical
packing energy, we predicted that lysine 189 and lysine 190 at the C-terminus may be crucial for
Bax membrane binding (Khaled A, unpublished data). However, this hypothesis has not been
validated in a cell model system.
Under physiological conditions, Bax usually resides in the cytoplasm and translocates to
mitochondria upon apoptotic stimuli. In its inactive form, Bax is also found in very low numbers
in mitochondrial membranes [7, 8]. Thus, Bax localizes to mitochondria as its major site of
action. Some studies have shown that Bax is involved in the formation of ion-conducting pores
in the mitochondria membrane [26-28]. Bax may functionally interact with components of the
3

mitochondrial inner membrane, like the adenine nucleotide transporter (ANT), the mitochondrial
F0F1 ATPase H+ pump, and the outer membrane voltage-dependent anion channel [29-31]. Bax
could also directly interact with the mitochondria channel Kv1.3 in lymphocytes [28]. Recently,
Bax was shown to participate in mitochondrial reactive oxygen formation in non-apoptotic
neuron cells [32, 33]. These findings imply that Bax’s interaction with mitochondria may play
an important role in regulation of mitochondrial function. However, the functional significance
of the interaction of Bax with mitochondria under non-apoptotic conditions has not been
determined. It is unknown whether the C-terminus of Bax is the critical region responsible for
the function of non-apoptotic form of Bax.

Here we investigate the role of Bax in the regulation of mitochondrial function under
non-apoptotic conditions and explore the molecular mechanisms for Bax translocation to
mitochondria under apoptotic stimuli. Using Bax+/+ and Bax-/- HCT-116 cells, we examined Bax
cellular localization and its effects on mitochondrial bioenergetics in non-apoptotic cells. We
further tested whether over-expression of full-length Bax in Bax-/- cells would restore
mitochondrial metabolic activity. We also over-expressed a C-terminal truncated Bax (BaxΔCT) in Bax-/- cells to determine whether the C-terminal helix of Bax is crucial for
mitochondrial bioenergetics. We showed that Bax localized to outer and inner mitochondrial
membranes in non-apoptotic cells, affecting citrate synthase activity, intracellular ATP
production and oxygen consumption. Loss of Bax led to impairment of mitochondria respiring
morphology and oxidative capacity, all of which can be restored by expression of full-length
Bax.

We also found that expression of the C-terminal truncated Bax can also restore

mitochondrial bioenergetics. These findings indicate that the constitutive expression of Bax in
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non-apoptotic cells is associated with mitochondria and is necessary for mitochondrial
bioenergetics.

To determine the molecular mechanisms for Bax targeting to mitochondria under
apoptotic stimuli, we previously performed in silico mutagenesis and predicted that lysines
189/190, in the C-terminal α9 helix, could regulate the membrane binding activity of Bax. A
series of in vitro mutagenesis were performed. Data presented here demonstrate that these
lysines are the functional domain contribute to the mitochondrial translocation of Bax under
apoptotic stimuli.

Expression of full-length Bax led to mitochondrial translocation and

apoptosis, whereas deletion of the α9 helix resulted in cytosolic retention, and no apoptosis.
Mutation of the two lysine residues changed the localization of Bax from either the cytosol or
mitochondria. We replicated the results achieved with full-length Bax by attaching just the last
20 residues of the α9 helix of Bax either to GFP or to a regulatory element: a degradation domain
(DD), and induced apoptosis upon expression in cells. We demonstrated that the α9 helix alone
promoted the mitochondrial translocation of either GFP or the DD and induced apoptosis. These
results indicate that the C-terminal α9 helix alone is sufficient to induce cell death and therefore
could be further studied for use in cancer therapies.
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CHAPTER 2: BAX SUPPORTS THE MITOCHONDRIAL NETWORK,
PROMOTING BIOENERGETICS IN NON-APOPTOTIC CELLS

Data presented here in part has been published at Am J Physiol Cell Physiol (February 2, 2011).

Introduction

As a pro-apoptotic protein, Bax has been established in participating in the induction of
apoptosis in response to a variety of apoptotic stimuli [1-3, 9]. Under physiological conditions,
Bax usually resides in the cytoplasm in most healthy cells, although a fraction of the cellular Bax
pool is found to be associated with the outer mitochondria membrane [7, 8]. Over the past
decades, most studies focused on how Bax translocates to mitochondria and triggers apoptosis,
little is known about the functional significance of Bax in non-apoptotic cells. Recently, the
essential role of Bax in non-apoptotic cells has emerged.

It has been reported that Bax

participates in mitochondrial production of reactive oxygen species in non-apoptotic sympathetic
neuron cells [32, 33]. However, how Bax does this is unknown. Since Bax uses mitochondria as
its major site of action, we postulated that Bax may interact with mitochondria and be involved
in the regulation of mitochondria function. To test this possibility, mitochondrial bioenergetics
were examined in Bax-containing (Bax+/+) and Bax-deficient (Bax-/-) HCT-116 cells. Our results
showed that some of the cellular Bax localized to the outer and inner mitochondrial membranes
in non-apoptotic cells and participated in citrate synthase activity, intracellular ATP production
and oxygen consumption.

Loss of Bax led to impairment of mitochondria respiration,
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morphology and oxidative capacity, all of which could be restored by expression of full length
Bax. These findings indicated that in non-apoptotic cells, the constitutive expression of Bax is
associated with mitochondria and is necessary for mitochondrial bioenergetics.

Materials and Methods

Cell Lines and Reagents
Bax+/+ and Bax-/- HCT-116 colorectal cancer cell lines (a kind gift from Dr. Bert
Vogelstein, John Hopkins University) were grown and maintained in McCoy’s 5A Medium
(Gibco), 10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.

FCCP

(carbonylcyanide-p-trifluoro-methoxyphenylhydrazone) (Sigma) was used at a concentration of
5 µM as described below. This was determined to be the optimal concentration after performing
a titration experiment (FCCP 0-25 μM) and measuring effects on 100 cell viability and ATP
production as described below.
Plasmids, Mutagenesis, and Transfection
PCR-directed deletion of the C-terminus of Bax to generate the C-terminal truncated
form of Bax (Bax- CT) was performed using untagged primer sets and was confirmed by
sequencing. BAX was PCR amplified from the template, pEGFP-Bax (a gift from Dr. Richard
Youle, NINDS, NIH). To examine the transient expression of the DD-tagged full length (BaxFL), DD-tagged Bax- CT, DD-tagged C-terminal Bax peptides (DD-CT-Bax) constructs,
bicistronic ProteoTuner vectors (CloneTech) containing these Bax inserts and green fluorescent
protein (GFP) separated by an internal ribosome entry site (IRES) were transfected into Bax+/+
7

and Bax-/- HCT-116 cells. Expression of the Bax constructs was induced upon the addition of
Shield 1 (CloneTech) at a concentration of 1uM.

The plasmid DNA was delivered at a

concentration of 1µg/mL using the TransIT-LT1 transfection reagent (Mirus) following
manufacturer’s protocol. Transfection efficiency was determined microscopically by visualizing
GFP expression after 18 hours, and ranged from 50-70%. Experiments were performed within
defined timeframes to ensure optimal cell viability, prior to any induction of apoptosis.
Measurement of Oxygen Consumption and Extracellular Acidification Rates
BAX+/+ and Bax-/- HCT-116 cells were cultured in a BD Oxygen Biosensor plate at a
concentration of 50,000 cells per well. The biosensor plate contained an oxygen-sensitive dye
embedded in a gas-permeable matrix. Based on the properties of this dye, oxygen quenches the
ability of the dye to fluoresce. The dissolved oxygen in the medium is depleted by the cells
metabolizing in the well, resulting in an increase in fluorescence. This allows a correlation of the
rate of oxygen consumption to be made. The plate was read at 37ºC on an EnVision plate reader
(PerkinElmer) using ex/em wavelengths of 485/630nm. Fluorescence intensity was measured
every hour for 24 hours. For comparisons of oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR), Bax+/+ and Bax-/- HCT-116 cells were seeded at 40,000 cells/well in a
24 well Seahorse cell culture plate. Full-length and CT Bax constructs were transfected into
Bax-/- cells for measurement as well. The transfected cells were treated with shield 1 three hours
prior to reading to induce expression of the protein. Measurements were taken on the Seahorse
XF24 plate reader (Seahorse Bioscience). Values were normalized as changes relative to the
initial reading.
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Mitochondrial Staining, Fixed- and Live-Cell Imaging
For fixed cells, Bax+/+ HCT-116 cells were plated onto coverslips coated with 10µg/mL
laminin (Invitrogen). Cells were plated at a density of 50,000 cells/well and were fixed by
methanol. The cells were then probed with anti-BAX (N-20; Santa Cruz) and anti-HSP60 (H300; Santa Cruz) antibodies, followed by FITC and CY3 secondary antibodies. Images were
scanned using the LSM 510 (Zeiss) with a 100x/1.4 plan-apochromat objective. The scanned
image was processed using the Zen 2009 software (Zeiss). For live cell imaging, BAX+/+ and
BAX-/- HCT-116 cells were grown and plated in 24-well glass bottom dishes (MatTek) that had
been pretreated with 1N HCl and coated with10ug/mL laminin. The cells were plated at 10,000
cells per well and allowed to grow over night. Bax-FL or Bax- CT constructs were transfected
using the TransIT-LT1 transfection reagent (Mirus) and expressed as previously described At 18
hours post-transfection, cells were incubated with 1uM MitoTracker Red 580 or 5µM 10-Nonyl
Acridine Orange (NAO) (Molecular Probes) in McCoy’s complete media for 30 minutes prior to
imaging. Treatments with 5µM FCCP were done 15 minutes prior to imaging. Fluorescent
images were acquired with the UltraView spinning disc confocal system (PerkinElmer) with
AxioObserver.Z1 (Carl Zeiss) stand, and a Plan-Apochromat 63x/1.4 Oil DIC objective. Z-stack
projections of the scanned images were generated and modified within the Volocity image
processing program (PerkinElmer).
Sub-cellular Fractionation and Immunoblots
Bax+/+ and Bax-/- HCT-116 cells were plated in 75cm flasks and grown to 70-80%
confluence. Cells were transiently transfected with the Bax-FL or Bax- CT constructs and
protein expressed as previously described. At 18 hours post transfection, the cells were lifted and
9

pelleted.

The pellets were resuspended and lysed according to the protocol from the

Mitochondrial Enrichment Kit (Pierce).

Note that a low speed centrifugation step in the

mitochondrial enrichment process ensures that only intact and unfragmented mitochondria are
isolated. The enriched mitochondria were layered on an iodixanol gradient (6%, 10%, 15%,
20%, 23%, and 27%) and subjected to ultracentrifugation using an Optima L-100XP
Ultracentrifuge for 2 hours at 145,000 rcf in a SW55.1 swing bucket rotor (Beckman Coulter).
After centrifugation, each sample was unloaded in 500uL fractions using a fraction recovery
system (Beckman Coulter), and washed in ice cold PBS twice (18,000 rcf, 30 minutes) to remove
residual iodixanol. The pellets from each of these fractions were resuspended in 1x loading
buffer and run on 8-16% Tris-glycine gradient gels (Invitrogen). The gels were transferred to
PVDF membranes and probed with primary antibodies to Bax (N-20; Santa Cruz), Prohibitin
(ABCAM), and GRP78 (Santa Cruz), followed by incubation with the appropriate HRP
conjugated

secondary

antibodies

(Santa

Cruz,

Cell

Signaling)

and

developed

by

chemiluminescence (Pierce).
Proteinase K Digestion of Membrane Bound Proteins
Bax+/+ and Bax-/- HCT-116 mitochondria were isolated as above. The mitochondria
were then treated with Proteinase K (Sigma) (10 µg/ml) for 5, 10, 15 or 20 minutes in order for
the outer mitochondrial membrane associated proteins to be digested.

The reaction was

terminated with PMSF [35]. The mitochondria were then washed with isotonic buffer, pelleted,
resuspended in 1X sample buffer and run on 12% acrylamide gels in parallel with untreated
mitochondria. The gels were transferred to PVDF membranes which were then probed with Bax
(N-20; Santa Cruz), as well as Bcl-XL (2762, Cell Signaling) primary antibodies, followed by
10

incubation with anti-mouse or anti-rabbit IRDye 800CW secondary antibodies (Licor). The
membranes were imaged using the Licor Odyssey Infrared Imaging system. Densitometry
measurements were made using Image J.
Measurement of ATP production and Mitochondrial Membrane Potential
Cells were seeded and treated in 24 well plates overnight. The cells were then lifted,
counted and seeded in 96-black well flat-bottom plates at a density of 4,000-5,000 cells/well. To
uncouple oxidative phosphorylation, 5µM FCCP was added to the cells two hours prior to
analysis of ATP concentration. ATP levels were quantified using the ATPLite 1-Step assay kit
(PerkinElmer).

Luciferase activity, reported as Relative Luminescence Units (RLU), was

measured on an EnVision (PerkinElmer) plate reader. The luminescence was normalized to the
number of cells/well.

Additionally a standard curve of known ATP concentrations was

established to ensure that the experimental values were within an accurate range. Background
signal was corrected for by subtracting the values of an empty plate. In addition, as the
fluorescence of MitoTracker Red 580 (Invitrogen) is a result of oxidation of the compound
within the mitochondrial matrix, changes in MitoTracker fluorescence intensity was used to
assess the qualitative and quantitative efficiency of the electrochemical potential (the relative
oxidative capability of actively respiring mitochondria [36]. Measurements of mitochondrial
content, membrane potential, and viability were done by staining the cells with both ethidium
bromide (Fisher Scientific) and NAO (6).

Briefly, 500,000cells/sample was stained with

25ng/mL NAO and 40ng/mL ethidium bromide for 10 minutes. The cells were then washed 3
times with 0.1% BSA in PBS at 4ºC for 10 minutes at 1000g. The cells were read using the C6
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flow cytometer (Accuri) using the FL1 and FL3 channels. Data was analyzed using FCSExpress
(DeNovo).
Measurement of Citrate Synthase Activity
Isolated mitochondria from Bax+/+and Bax-/- HCT-116 cells were assayed for citrate
synthase activity. The citrate synthase enzyme catalyzes the reaction: CoA-SH + DTNB  TNB
+ CoA-S-S-TNB. The rate of TNB formation is linear and has a measurable absorbance at
412nm.

The rate of TNB generation (μMol/ml/min) was measured by spectrophotometry

(Beckman Coulter SD8000) for 200 seconds. Mitochondrial samples were run in Tris buffer to
determine inner mitochondrial membrane integrity (reported as % ruptured mitochondria), or
Tris buffer with Triton X-100 to determine citrate synthase activity.
Measurement of Mitochondrial DNA
DNA was isolated from Bax+/+ and Bax-/- HCT116 cells using TRIZOL Reagent
(Invitrogen) followed by ethanol precipitation. Resuspended DNA pellets were analyzed for
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) content. Primers for the detection of
the nuclear housekeeping gene β-actin and for the mitochondrial DNA encoded ATPase
(MTATP) genes were as follows: β-actin (forward): 5’-GAA ATC GTG CGT GAC ATC
AAAG; (reverse): 5’-TGT AGT TTC ATG GAT GCC ACAG. MTATP (forward): 5’-AAT ATT
AAA CAC AAA CTA CCA CCT ACC; (reverse): 5’- TGG TTC TCA GGG TTT GTT ATA
[37]. The PCR was carried out in a 7500 Fast real-time PCR system (Applied Biosystems). All
reactions were carried out in 20μl of total reaction volume containing 1μg/μl total DNA,
appropriate primers and Fast SYBR Green Master Mix (Applied Biosystems). Each reaction
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underwent a 30 s 90 ºC denaturation followed by 40 cycles of 30 s at 60 ºC then 3 s at 95 ºC. All
samples were analyzed in triplicate. The relative amount of mtDNA (normalized to nuclear
content) is represented as 2ΔCt, calculated using the following equation: ΔCt = (CtmtDNA
/CtnDNA) - (CtnDNA/CtnDNA), where Ct is the cycle threshold for each condition.
Statistics
All data in this study are expressed as means ± SEM. Statistical analysis of differences in
data between the groups was determined using Prism for Windows, Version 5.02 (GraphPad
Software Inc).

Results

Bax is essential in mitochondrial bioenergetics
To determine whether Bax has a previously unrecognized non-apoptotic activity, we
examined mitochondrial structure, function and bioenergetics in Bax+/+ and Bax-/- HCT-116
colon cancer cells. Mitotracker Red 580 fluorescence intensity was used as an indicator of
oxidative capacity and to visualize actively respiring mitochondria [38]. Live-cell imaging was
performed to ensure that fixatives would not disrupt MitoTracker uptake. As shown in Figure
1A, when Bax is present, we observed respiring mitochondria that displayed elongated and
tubular shape with a loosely dispersed branching network. In contrast, when imaging of the Bax/-

cells, we observed that the respiring mitochondria were numerous but appeared less elongated

due to the deficiency of Bax (Fig. 1B). To verify that the observed differences in functional
morphology upon Mitotracker staining were not due to alterations in the fission/fusion process,
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treatment with Mdivi 1, a chemical inhibitor of DRP1that prevents fission by blocking the early
stages of DRP1 assembly, resulted in uniform changes in MitoTracker fluorescence that were
independent of Bax (data not shown).
To determine whether the differences observed in Mitotracker staining (Figs. 1A, 1B)
were caused by altered mitochondrial density induced by loss of Bax, we probed both Bax+/+ and
Bax-/- HCT-116 cells with N-nonyl acridine orange (NAO). NAO accumulates in mitochondria
by binding to phospholipids, specifically cardiolipin [39, 40]. Hence NAO accumulation is
independent on mitochondrial respiration and would directly show mitochondrial content. As
shown in Figures 1A and 1B, NAO incorporation in mitochondria was similar in both Bax+/+ and
Bax-/- HCT-116 cells. This was confirmed by the measurement of total NAO fluorescence in
each cell population (Fig. 1C). Hence, total mitochondrial density or content was independent of
Bax expression. To confirm results from NAO staining, we perform a quantitative experiment
by measuring total mitochondrial DNA (mtDNA) relative to nuclear DNA (nDNA). We found
no detectable differences in mtDNA content between Bax+/+ and Bax-/- HCT-116 cells (data not
shown). To demonstrate that Bax+/+ and Bax-/- HCT-116 cells were equally viable, we stained
cells with NAO and ethidium bromide (EB). EB stains DNA only when the cell membrane is
ruptured, as it is in cultured apoptotic cells. Representative data displayed in Fig. 1D revealed
that there were no significant Bax-dependent differences in overall viability. The viability of cell
lines used in all experiments reported herein was consistent with the data shown in Figure 1D.
Together, these results suggest that the observed morphological differences detected by
mitochondrial tracker staining were due more to a functional defect rather than decreased
mitochondrial content.
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To explore a possible functional defect upon BAX loss that was revealed by Mitotracker
staining, we examined the electrochemical properties of the mitochondria in the two HCT-116
Bax variants using the uncoupling agent, FCCP. FCCP is a hydrophobic compound that carries
protons across the IMM, releasing these protons into the matrix allowing for the dissipation of
the chemiosmotic gradient. A titration of FCCP was previously performed to determine the
optimal concentration of FCCP for use, that is, caused the least effect on cell viability and the
most effect on ATP production (data not shown). When treated with FCCP, Bax+/+ mitochondria
displayed a stronger intensity of Mitotracker fluorescence compared to untreated cells (Fig. 2A,
2C). This was not observed in Bax-/- cells (Fig. 2B, 2C). Although relaxation of Mitotracker
fluorescence quenching has been reported with FCCP, we do not think this artifact is the reason
for the observation made with Bax+/+ cells, since the increase in Mitotracker fluorescence was
not repeated in Bax-/- cells. Quantification of the effect of FCCP treatment revealed a two fold
increase in MitoTracker fluorescence in Bax+/+ cells compared to untreated cells that was not
observed with Bax-/- cells (Fig 2C). We propose that, in Bax+/+ cells, the FCCP-mediated
uncoupling of the electron transport system results in the rapid oxidation of matrix substrates,
such as MitoTracker Red 580, which can be detected as an increase in MitoTracker fluorescence
[39]. This does not occur in Bax-/- cells, suggesting that loss of Bax may cause a defect in
mitochondrial oxidative capacity.

Bax-/- cells also had significantly decreased levels of

intracellular ATP as compared to Bax+/+ cells (Fig. 2D). Furthermore, FCCP treatment resulted
in a marked drop in ATP levels in Bax+/+ cells, but not in Bax-/- cells (Fig. 2D). Note that a
previous titration of FCCP concentrations correlated with ATP amounts detected, indicating that
we were primarily assessing changes in ATP production (data not shown).
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To determine whether the loss of ATP in Bax-/- cells was due to abnormal bioenergetics,
we measured glycolysis and oxygen consumption using a Seahorse XF analyzer. Metabolic
activity in Bax+/+ and Bax-/- HCT-116 cells was assessed by plotting the oxygen consumption rate
[OCR], a measure of mitochondrial respiration, against the extracellular acidification rate
[ECAR], an indicator of glycolysis. Comparing changes that occur in aerobic and glycolytic
metabolism, shown in Figure 2E, revealed that Bax+/+ cells had increased oxygen consumption
(OCR) and decreased glycolytic activity (ECAR) relative to Bax-/- cells; hence cells deficient in
Bax were more dependent on glycolysis for their energy needs. A separate measure of oxygen
consumption, using an alternative method, further confirmed these findings (Fig. 2F). Taken
together, these results indicated that the decreased levels of ATP observed in Bax-/- cells were
likely due to depressed respiration, suggesting that cells lacking Bax had a significant defect in
oxidative capacity.
Bax associates with mitochondria and contributes to ATP production
Since we showed a non-apoptotic function for Bax in the regulation of mitochondrial
metabolism, immunofluorescence was performed to determine whether Bax localizes to
mitochondria in the absence of apoptosis. As shown in Figure 3A, a partial overlay of Bax with
mitochondria (HSP-60 staining for mitochondrial marker) was observed in Bax+/+ HCT-116
cells. To determine the interaction of Bax with mitochondria under standard growth conditions,
ultra centrifugation of enriched mitochondria was performed to examine the localization of Bax.
Cell lysates were prepared from cells that had the same viability. The enriched mitochondrial
lysate was layered on an iodixanol gradient and subjected to ultracentrifugation as described in
methods. Separation of organelles was based on density, which is a function of the protein-lipid
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ratio of the organelles.

Western blot analysis of the gradient fractions for Prohibitin

(mitochondrial content) (Fig. 3B) showed that the distribution of the mitochondria between
Bax+/+ and Bax-/- HCT-116 cells was similar (across the 20-23% fractions). Approximately 7%
of the total endogenous Bax was detected in the non-apoptotic Bax+/+ cells associated with the
mitochondrial fractions, while no Bax was detected in Bax-/- cells (Fig. 3B).
To determine whether Bax was loosely associated with mitochondria (i.e. bound to the
outer mitochondrial membrane (OMM)) or whether it was sequestered within an inner membrane
compartment (IMM). Enriched mitochondrial lysates were treated with Proteinase K for 5 to 20
minutes. Digested lysates were analyzed by SDS-PAGE and immunoblotted with antibodies to
detect Bax and, as a control, BCL-XL. BCL-XL is mainly an OMM localized protein and
sensitive to protease digestion. We found that treatment with Proteinase K resulted in 50-60%
lysis of Bax, compared to BCL-XL, in which 77-100% of the protein was lysed (Fig. 3C).
Although in the same sample there was less BCL-XL protein detected compared to Bax, an
increase in the amount of BCL-XL digested occurred over time, while Bax was mostly digested
within 5 minutes. These results suggest that a significant amount of Bax was sequestered within
the mitochondria and not accessible to be digested by the protease. Hence Bax has both outer
and inner mitochondrial localization, supporting its proposed role in mediating mitochondrial
respiration. The ability of Bax to regulate mitochondrial metabolism was further demonstrated
by measurements of citrate synthase activity, which localized to the mitochondrial matrix and is
one of the first enzymes of the tricarboxylic cycle. As shown in Figure 3D, Bax-/- cells had
reduced levels of citrate synthase activity in comparison to Bax+/+ cells.
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Expression of full-length Bax restores mitochondrial metabolic activity in Bax-/- cells
Since cells lacking of Bax displayed impaired mitochondrial metabolic activity, we
determined whether restoring Bax to deficient cells would rescue mitochondrial metabolic
activity. Over-expression of full-length Bax (Bax-FL) in Bax-/- cells resulted in recovery of
respiring mitochondria morphology as observed in Bax+/+ cells (Fig. 4A). Western blot analysis
of density gradients showed that ~2.5% of the total expressed protein associated with
mitochondrial fractions (Fig. 4B). We also observed a three-fold increase in ATP production
upon the expression of Bax-FL, whereas this increase in ATP production was inhibited by
treatment with FCCP (Fig. 4C), suggesting that that Bax-FL could rescue ATP production
through oxidative phosphorylation. ECAR/OCR measurements further confirmed that expression
of Bax-FL could increase oxygen consumption and reduce glycolytic activity, indicating that
Bax was a critical regulator of these activities (Fig. 4F). To determine the contribution of the Cterminal helix of Bax to mitochondrial bioenergetics, over-expression of C-terminal truncated
Bax (Bax-ΔCT) in Bax-/- cells was performed. As shown in Figure 4D, expression of Bax-ΔCT
did not restore the respiring mitochondrial morphology seen in the presence of Bax, suggesting
that the C-terminal domain of Bax is essential to regulate mitochondrial metabolic activity by
Bax. The removal of this C-terminal helix also resulted in a scattered localization of Bax-ΔCT,
which was supported by the altered banding pattern in the gradient fractions (Fig. 4E). Even
though mitochondrial targeting was deregulated in this mutant, Bax-ΔCT was found in the
mitochondrial fractions (~9%, Fig. 4E), and was able to restore ATP production as effectively as
Bax-FL (Fig. 4E). This was further demonstrated by measurements ECAR/OCR, which showed
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that expression of Bax-ΔCT was able to restore metabolic balance in Bax-/- cells, almost the same
levels as Bax-FL (Fig. 4F).
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Figure 1. Loss of Bax leads to altered respiring mitochondria morphology.
Bax+/+ HCT-116 cells (A) and Bax-/- HCT-116 cells (B) were treated with MitoTracker Red
580 or NAO prior to imaging as described in Methods. Live cell images were obtained using the
UltraView (PerkinElmer) spinning disc confocal system. Images are representative of three
replicates per condition. Insets are 10X magnification of the two highlighted areas in each field.
(C) and (D) To assess mitochondrial density (C) and viability (D), 500,000 cells/sample were
stained with NAO (C) or NAO and ethidium bromide (EtBr) (D) for 10 minutes. Fluorescence
output was read using the FL1 and FL3 channels on a C6 flow cytometer (Accuri). Each
experiment was performed in triplicate for each cell line variant. (contributed by R. Boohaker)
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Figure 2. Loss of Bax leads to reduced mitochondrial oxidative capacity.
Bax+/+ HCT-116 cells (A) and Bax-/- HCT-116 cells (B) were treated with FCCP in McCoy’s
complete media for two hours prior to imaging. Live cell images were obtained using the
UltraView spinning disc confocal system. The stand was a Zeiss AxioObserver Z.1 with a PlanApochromat 63x/1.4 Oil DIC objective. Insets are 10X magnification of the two highlighted
areas in each field. Images are representative of three separate experiments with two replicates
per condition. (C) Calculation of Mitotracker fluorescence intensity was done with Velocity
software by averaging the mean intensity of the pixels in each fluorescent cell. (D) ATP
concentration was assessed by measuring the activity of Luciferase as relative luminescence
units (RLU). (E) OCR and ECAR data obtained from the Seahorse XF24 Analyzer was
calculated based on the oxygen consumption and acidification rates of 40,000 cells per well. The
values were pooled from three separate experiments and normalized to changes from the initial
rate, n=9. (F) Oxygen consumption in both Bax+/+ and Bax-/- cells was measured over time as a
function of increased fluorescence. Fluorescence, oxygen biosensor, and ATP data are
representative of n=6. The values for the ATP, OCR and ECAR assays were normalized to cell
number per well, and statistics were done using One-way ANOVA with Dunnett’s post-test
anlysis. *P < 0.05, **P < 0.01 and ***P < 0.001. (contributed by R. Bohhaker)
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Figure 3. Bax associates with mitochondria in non-apoptotic cells resulting in reduced citrate
synthesis activity.
(A) Bax+/+ HCT-116 cells were fixed and stained with the indicated fluorochrome-conjugated
antibody as described in Methods. Confocal microscopy of cells shows endogenous Bax (green),
the mitochondrial protein, HSP60 (red), and the merged field (yellow) indicating co-localization
of Bax with HSP60. Images were acquired with LSM 510 using 100 x/1.4 Oil DIC objectives
and are representative of ten different images scanned from three separate experiments. (B)
Enriched mitochondrial lysates of membrane-bound proteins were prepared from both Bax+/+
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and Bax-/- HCT-116 cells and subjected to differential ultracentrifugation as described in
methods. Gradient fractions collected were analyzed by SDS-PAGE and membranes probed for
the presence of Bax, prohibitin (mitochondria), and GRP78 (ER). Each blot shown is
representative of three independent experiments. (C) Western blot analysis of mitochondria
isolated from BAX+/+ cells shows the effects of Proteinase K digestion on mitochondrial
membrane proteins over time. The extent of the digestion was calculated based on the percent
change in densitometry between the treated and untreated samples. (D) The assessment of citrate
synthase activity was determined by the rate of formation of thionitrobenzoic acid as described in
methods. The rate of activity is shown as μMol/ml/min. Background levels of citrate synthase
activity in spontaneously ruptured mitochondria are included as controls. The data encompasses
two separate experiments for a total of n=4 per sample. Statistics were calculated using unpaired
Students t-test. *P < 0.05. BCL-XL is mainly an OMM localized protein and sensitive to
protease digestion. (parts contributed by R. Boohaker and K. Nemec)
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Figure 4. Expression of full-Length Bax restores mitochondrial association and ATP production
in Bax-/- cells.
Bax-/- 716 HCT-116 cells were transfected with a ProteoTuner bi-cistronic vector expressing
either full-length (FL) Bax (A, B) or Bax- CT(C, D) and GFP(A, C) Cells were grown on
MatTek plates as described in Methods, and transiently transfected (efficiency 60-70%). Shield
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1 was added to induce expression. Transfected cells were imaged based on GFP expression, and
MitoTracker Red was used for mitochondria visualization. Live cell images were obtained using
the UltraView spinning disc confocal system. The stand was a Zeiss AxioObserver Z.1 with a
Plan-Apochromat 63x/1.4 Oil DIC objective with a resolution of 0.124 m. Insets were acquired
at 10 X magnifications. Post-acquisition processing was done using Velocity software. (B, D)
Bax-/-HCT-116 cells were transfected with either Bax-FL or Bax- CT as described above.
Mitochondrial enriched lysates were subjected to differential ultracentrifugation and SDS-PAGE
as described in methods. Membranes were probed with antibodies for Bax, prohibitin
(mitochondria) and GRP78 (ER). Images are representative of three independent experiments.
(E) Bax+/+ and Bax-/- HCT-116 cells transiently transfected with Bax-FL or Bax- CT ( C)
were treated with and without FCCP and analyzed for changes in ATP levels as described in
Methods. (F) Bax+/+ HCT-116 cells, Bax-/-HCT-116 cells, and Bax-/- HCT-116 cells,
transiently transfected with Bax-FL (FL) or Bax- CT ( CT or DCT,) were analyzed for changes
in OCR and ECAR as in methods. One-way ANOVA was used for statistical analysis.
Microscopy and ATP data is representative of two experiments each with three replicates. OCR
and ECAR data are representative of two experiments with a total of six replicates. Statistical
results for OCR and ECAR assays are *p <0.05for Bax-/- vs. Bax-FL and Bax-/- vs. Bax- CT.
*** p < 0.001 for the ATP assay. (parts contributed by R. Boohaker)
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Discussion

The Bcl-2 family proteins that tightly control the mitochondrial pathway of apoptosis
have been classified into pro- and anti-apoptotic members [7,9]. Among which Bax is a proapoptotic protein, and its activation is a highly regulated, multi-step process that involves Bax
conformational changes, mitochondrial translocation and oligomerization, and ultimately leading
to mitochondrial dysfunction and apoptotic cell death [1-3,7]. Although the precise mechanisms
remain unclear, it is generally accepted that Bax conformational changes and translocation to the
mitochondria are critical events for Bax to exert it apoptotic activity upon apoptosis stimuli [7,9].
In dying cells the accumulations of activated Bax at the mitochondrial outer membrane trigger
the release of apoptotic mediators, such as cytochrome c, from the intermitochondrial membrane
space. Thus, Bax localizes to and uses mitochondria as its major site of action. In addition to its
apoptotic form, Bax is also constitutively expressed in non-apoptotic cells and resides in a
soluble, cytosolic form or associated with mitochondria [7, 8].

Several studies have

demonstrated that this non-apoptotic form of Bax may be involved in mitochondrial function
such as reactive oxygen formation and ion channel conduction [32, 33]. However, relatively
little is known about the direct role that the inactive form of Bax plays in regulation of
mitochondrial function.
In the present study, we assessed the direct role of non-apoptotic Bax in mitochondrial
function in non-apoptotic cells by using the Bax+/+ and Bax-/- HCT-116 cell model system. The
results showed that Bax localized to outer and inner mitochondrial membranes in non-apoptotic
cells and participated in citrate synthase activity, intracellular ATP and oxygen consumption.
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Loss of Bax led to impairment of mitochondria respiring morphology and oxidative capacity, all
of which could be restored by expression of full-length Bax. These findings indicated that under
normal conditions, the constitutive expression of non-apoptotic Bax is associated with
mitochondria and is necessary for mitochondrial bioenergetics.
Under non-apoptotic conditions, Bax is present in a soluble, cytosolic form or associated
with mitochondria as a monomer. A small amount of “active” (non-apoptotic) BAX associated
with healthy mitochondria may contribute to the regulation of functional architecture and
bioenergetics of mitochondria.

This leads to the hypothesis that BAX associated with

mitochondria under non-lethal conditions could be restricted by the lipid and protein composition
of the organelle membrane [41, 42]. Apoptosis induces changes in mitochondria that could help
recruit Bax, while, in the absence of apoptosis the outer mitochondrial membrane environment is
less likely to support the translocation of Bax. In mitochondria from healthy cells, a few BAX
monomers or dimers may insert into the mitochondrial membranes to form small pores, but this
process needs to be tightly regulated. Bax may also functionally associate with components of
the mitochondrial inner membrane, like the adenine nucleotide transporter (ANT), the
mitochondrial F0F1 ATPase H+ pump, and the outer membrane voltage-dependent anion channel
(VDAC) [29-31]. Thus, it is more feasible for Bax to be interacting with existing mitochondrial
proteins. This possibility is supported by our findings that a portion of Bax was sequestered
within the mitochondria, perhaps interacting with an IMM protein. Hence, the amount of Bax
associated with mitochondria in non-apoptotic cells would be constrained by the availability of
the binding partner(s), although most were discovered in the context of an apoptotic scenario
[29-31]. In addition to ANT and VDAC, many other proteins are known to interact with Bax,
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including factors that mediate changes in the mitochondrial network such as fission or fusion
proteins like Drp1[43], Mfn-2 [44] or endophilin B1 (Bif-1) [45] as well as other regulatory
proteins such as cyclophilin D or Ku70[46]. Although this may seem speculative, the excess of
circumstantial evidence for the interaction of Bax with healthy mitochondria highlights a real
need for further study to determine whether these proteins act to facilitate Bax’s role in
mitochondrial bioenergetics.
A recent proteome-wide quantification of proteins analysis conducted in Bax-containing
and Bax-deficient HCT-116 cells shows that a number of mitochondrial proteins, like VDAC,
were found to be down regulated significantly upon loss of Bax [48]. Two enzymes essential for
glucose metabolism and ATP production were also decreased in Bax deficient cells: Glucose-6phosphate isomerase was reduced over 10-fold and citrate synthase was reduced over 7-fold.
Consistent with this, our results showed reduced citrate synthase activity in Bax-/- HCT-116 cells.
Loss of critical metabolic components exacerbates the inability of Bax deficient cells to produce
energy from glucose. However, the impairment of citrate synthase activity in the Bax -/- cells was
restored by the reintroduction of Bax into these cells with dramatically increased respiration and
ATP production.

These data strongly supports the concept that Bax plays an important

homeostatic role in supporting growth and metabolism.
In conclusion, we have shown that Bax localized to outer and inner mitochondrial
membranes in non-apoptotic cells and participated in citrate synthase activity, intracellular ATP
production and oxygen consumption. Loss of Bax led to impairment of mitochondria respiring
morphology and oxidative capacity, all of which can be restored by expression of full-length
Bax. Bax C-terminal deletion can also restore mitochondrial bioenergetics. These findings
29

indicate that the constitutive expression of inactive form Bax is associated with mitochondria and
is necessary for mitochondrial bioenergetics.
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CHAPTER 3: THE C-TERMINAL α9-HELIX OF BAX IS THE EFFECTOR
DOMAIN OF APOPTOTIC FUNCTION

Introduction

Bax participates in the induction of apoptosis in response to a variety of apoptotic signals
[1]. Although the precise mechanism responsible for its apoptotic activity remains undefined,
Bax conformational changes and translocation into the mitochondria are recognized as the key
events triggering mitochondria-dependent apoptosis.

Once inserted into the mitochondrial

membrane, Bax undergoes conformational changes, leading to membrane destabilization. This
leads to the release of cytochrome c, SMAC/DIABLO, and Htra2/Om from the mitochondrial
intermembrane space into the cytoplasm where they amplify the caspase cascade, resulting in
apoptotic cell death. Although the pro-apoptotic activity of Bax is well-established, how Bax
translocates to mitochondria and triggers apoptosis remains unclear.
Recently, specific regions in the C terminus of Bax have been found to be critical in the
regulation of Bax binding to mitochondria [1, 8, 13, 48]. In some studies, the C-terminus has
been considered to be required for Bax binding to mitochondria and represents a transmembrane
domain to facilitate translocation and insertion of Bax to the outer membrane of mitochondria
[12, 13, 18, 49, 50]. Other reports suggest that the C-terminal anchor is not required for Bax
translocation during apoptosis [14, 22, 25]. In these latter studies, deletion of the C-terminal 22
amino acids failed to block recruitment of Bax to mitochondria during apoptosis [22]. Thus,
whether the C-terminus of Bax is a membrane binding domain or a regulatory domain remains to
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be analyzed. Recently, we performed computational-mutagenesis to identify possible structural
elements of the C-terminal necessary for Bax membrane binding activity. Based on variations in
helical packing energy, we predicted that lysines 189/190, in the α9 helix at the C-terminal, may
be crucial for Bax membrane insertion (Khaled A, unpublished data). Therefore, the purpose of
the present study was to determine whether lysines189/190 at the C-terminal helix are the
structural elements that mediate the binding of Bax to mitochondria and regulate its apoptotic
activity. Data presented here demonstrated that the C-terminal α9-helix is the functional domain
responsible for the apoptotic function of Bax. Expression of full-length Bax (Bax-FL) led to
mitochondrial translocation and apoptosis, whereas deletion of the α9 helix resulted in cytosolic
retention and no apoptosis. Mutation of the two lysine residues changed localization of Bax to
mitochondrial membranes. These results were replicated by attaching the last 20 amino acids of
the α9 helix of Bax to either GFP or to a regulatory element, a degradation domain (DD). We
demonstrated that the α9 helix alone promoted the mitochondrial translocation of either GFP or
the DD and increased apoptosis. These results indicated that the C-terminal α9 helix of Bax
alone is sufficient to promote cell death.

Materials and Methods

Cell lines and Reagents
The Flp-In T-REx-293 cell line (Invitrogen) was derived from 293 human embryonic
kidney cells and stably expresses the lacZ-Zeocin fusion gene and the Tet repressor. The 293
cell line was maintained in D-MEM (high glucose), 10% FBS (tetracycline-reduced), 2 mM L32

-/-

glutamine and 1% Penicillin-Streptomycin (DMEM complete medium). The HCT116 Bax and
Bax

+/+

colorectal cancer cell lines [51] (a kind gift from Dr. Bert Vogelstein, John Hopkins

University) were maintained in McCoy’s 5A media, 10% FBS and 1% Penicillin-Streptomycin
(McCoy’s complete medium).
Plasmids, Mutagenesis and Transfection
PCR-directed mutagenesis of the C-terminus of Bax was performed using HA-tagged
primer sets (Table 1), with mutations incorporated within the primer sequences. For inducible
expression of Bax wild-type (WT) and mutant proteins, we employed the Flp-In T-REx System
(Invitrogen). Bax constructs were amplified by PCR from the template, pEGFP-Bax (a gift from
Dr. Richard Youle, NINDS, NIH), digested with EcoRV and cloned into the plasmid, pcDNA5/
FRT/TO, which undergoes recombinase-mediated DNA recombination at the Flp Recombination
Target (FRT) site when co-expressed with the pOG44 plasmid that constitutively expresses the
Flp recombinase. All constructs were confirmed by sequencing. The pOG44 plasmid and the
pcDNA5/FRT/TO vectors were co-transfected into the Flp-In T-REx 293 cell line, at a ratio of
9:1, using Fugene transfection reagent (Roche) following manufacturer’s protocol. Stable Flp-In
T-REx expression cell lines were then selected for Blasticidin resistance (10μg/ml), Hygromycin
resistance (100μg/ml) and Zeocin sensitivity (200μg/ml). Bax expression in 293 cells was
induced by the addition of tetracycline (1μg/ml) and cells were assayed for the mitochondrial
translocation of Bax by immunoblotting as described below.
To generate the EGFP fusion C-terminus (amino acids 168-192) of Bax (EGFP-Bax-CT)
constructs, primers incorporating the C-terminus of Bax (Table 1) were used in a PCR to amplify
EGFP from the template pEGFP (Clontech), and the PCR insert was cloned into
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pcDNA5/FRT/TO as previously described. Bax-/-HCT-116 cells were transiently transfected and
cells assayed microscopically for EGFP expression 48 hours later.
To generate the DD-tagged Bax C-terminus (amino acids 173-192) wild-type (WT) or
EE, LL, and RR mutations, primers were annealed and ligated into the ProteoTuner vector
digested by EcoRI and BamHI. To generate the DD-tagged full-length WT Bax and CT-Bax,
the PCR product of Bax was digested with XhoI and EcoRI restriction endonucleases and ligated
into the ProteoTuner vector. The ProteoTuner IRES2 system also has the marker protein GFP
downstream to the internal ribosome entry sequence (IRES) and can be translated independently
of the DD-tagged Bax protein.
Mitochondrial Translocation Assay and Immunoblotting
To examine the mitochondrial translocation of Bax, HA-tagged full-length Bax and its
mutants were transfected into HEK293 cells and expression of Bax was induced by addition of
1μg/ml tetracycline for 24 hrs. To further determine the Bax C-terminal mutations on Bax
mitochondria translocation, EGFP-CT-Bax or Bax-ΔCT was constitutively expressed in Bax-/HCT116 cells for 24 hrs. We also examined whether DD-tagged Bax C-terminal peptide and its
mutants could affect Bax mitochondria translocation. DD-tagged FL-Bax and DD-tagged CTBax as well as it mutants (EE, LL and RR) were transfected into Bax+/+ and Bax-/- HCT-116 cells
for 24 hrs, then expression of these DD-tagged constructs were induced by the addition of shield
for 4 hrs. The cells were then lysed and mitochondrial and cytosolic proteins were isolated using
a mitochondrial enrichment kit (Pierce) according to the manufactor’s instructions. The final
mitochondrial pellet was washed in 1M NaCl (in place of carbonate (pH 11) buffers) to remove
any proteins peripherally associated with mitochondria. Mitochondrial and cytosolic protein
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fractions were loaded on 12-15% SDS-PAGE gels, transferred to PVDF membranes and probed
with the appropriate primary antibodies. For detection of HA-tagged Bax, an anti-HA mouse
monoclonal antibody was used (16B12, Covance). Anti DD monoclonal antibody (631073,
Clontech) was used to probe for DD-Bax.

Antibodies for the loading controls and for

mitochondrial and cytosolic contents were: endogenous Bax (N-20 Santa Cruz), prohibitin (Ab2, Fitzgerald) and p38 MAP kinase (MAPK) (C20, Santa Cruz). A mouse polyclonal antibody
was used for detection of EGFP (A.v. antibody, Clontech). Appropriate secondary rabbit or
mouse antibodies conjugated to horseradish peroxidase (HRP) and enhanced chemiluminescence
kit (Pierce) was used for visualization following the manufacturer’s protocol.
Fixed- and Live-Cell Imaging
To determine whether expression of the C-terminal of Bax mutations affect the apoptotic activity
of Bax, Bax-/- HCT-116 cells were grown on coverslips coated with 200 μg/ml poly-L-lysine
(Sigma) and co-transfected with both EGFP and one of the HA-tagged Bax mutant constructs
using Mirus LT-1 reagent following manufacturer’s protocol. After 48 hours, apoptotic cell
death was assessed by loss of EGFP-expressing cells. Images were acquired using a Nikon
Eclipse E1000 microscope (10X objective) with a SPOT RT camera.
To determine whether expression of DD-tagged Bax C-terminal peptides co-localizes
with mitochondria, Bax+/+ and Bax-/- HCT-116 cells were cultured for 24 hours on coverslips
pretreated with laminin. The DD-Bax C-terminal WT peptide and DD-Bax C-terminal EE, LL,
RR mutations constructs were transfected into the cells using Mirus LT-1 reagent according
manufacturer’s protocol. After 24 hrs, expression of the transfected peptides was induced by the
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addition of shield 1 for 4 hrs. Cells were fixed with 2% w/v formaldehyde/PBS for 15 minutes
and permeabilized using 0.05% Triton X-100/PBS for 15 minutes. After washing, cells were
incubated with primary antibodies HSP60 (H-300, Santa Cruz) and DD monoclonal antibody for
1 hour at room temperature, followed by incubation with secondary anti-rabbit-Cy3 (81-6115,
Invitrogen) and anti-mouse-Texas red (715076020, Jackson Immunoresearch) for 30 minutes.
After the final wash, cells were mounted with gel/mount medium (Mo1, Biomeda) and images
were acquired with UltraView (PerkinElmer) microscopy with a plan-apochromat 63 X /1.4 oil
objective. The scanned images were processed and Pearson’s correlation coefficients determined
using Velocity Version 5.5 (Perkin Elmer). Analysis of the images was completed through
Prism 5 (Graphpad) software.
Bax+/+ and Bax-/- HCT-116 cells were cultured in 24-well plates (MatTek Corporation) in
McCoy’s complete medium. Cells were transfected with the GFP-tagged C-terminal wild type
(KK), EE and LL mutants of Bax constructs into both Bax+/+ and Bax-/- HCT116 cells using the
TransIT-LT1 transfection reagent (Mirus) according to the manufacturer’s protocol.

After

transfection for two hours, time-lapse movies were made for 12 hrs using the UltraView
(PerkinElmer) spinning disc confocal system with AxioObserver.Z1 stand, and a PlanApochromat 10x objective. Snapshots were taken as indicated in the images.
The constructs of DD-Bax-C-terminal-WT, DD-Bax-CT-EE, DD-Bax-CT-LL, DD-BaxCT-RR were delivered as mentioned above for 48 hours. Cells were incubated with 1nM
MitoTracker Red 580 in McCoy’s complete media for 30 minutes at 37 °C prior to imaging.
Time-lapse movies were recorded for 5 hrs using the UltraView spinning disc confocal system
(PerkinElmer) with AxioObserver.Z1 (Carl Zeiss) stand equipped with a Plan-Apochromat 63x
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Oil DIC objective, in a humidity and temperature-controlled chamber (LiveCell). Z-stack
projections of the scanned images were generated within the imaging program, Volocity Version
5.5 (PerkinElmer). Post-acquisition snapshots were taken from time-lapse movies.at 0, 3 and
5hrs.
Detection of apoptotic cells by flow cytometry
Bax+/+ and Bax-/- HCT-116 cells were plated in 6-well plates, and cells transfected with
DD-Bax C-terminal WT, EE, LL, or RR mutants for 24 hrs, followed by treatment with Shield 1
to induce peptide expression for an additional 24 hrs.

Cells were collected at a final

concentration of 1 x 106 cells/ml in HBSS. Cells were then stained using the Violet Ratiometric
Membrane Asymmetry Probe/Dead Cell Apoptosis Kit (A35137, Invitrogen) according the
manufacturer’s protocol by adding F2N12S solution and SYTOX® AADvanced™ dead cell
stain solution to each sample. Analytes were incubated at room temperature for 5 minutes, and
then analyzed using the BD FACSAria II flow cytometer. F2N12S was visualized with a laser
source at 405nm and emissions collected at 530nm and 585nm, and excitation of SYTOX®
AADvanced™ visualized at 488nm and emissions collected at 695nm.
Statistical Analysis
Data were presented as mean ± SD. Statistical analysis was determined using Prism for
Windows, Version 5.02 (GraphPad). A p value under 0.05 was considered a significant
difference.
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Results

The C-terminal α9 helix is critical for Bax intracellular localization and apoptotic activity
To verify our predictions derived from our computational studies, we performed a series
of mutagenesis experiments targeting the C-terminal of Bax, as summarized in Table 2. We
generated wild-type (WT) and N- or C-terminal deleted Bax mutants as well as the C-terminal
Lys189/190 mutants. The inducible expression of Bax mutants in 293 cells, upon addition of
tetracycline, was examined by immunoblot. In this cell model system, the inducible low
expression of Bax in these cells did not cause apoptosis. p38 MAPK and prohibitin were used as
indicators for cytosolic and mitochondrial content, respectively. Expression of WT Bax was
found both in cytosolic and mitochondrial extracts. The N-terminal deleted Bax lacking residues
1-19 (Bax-ΔNT), was localized primarily to mitochondria, while the C-terminal deleted Bax
lacking residues 173-192 (Bax-ΔCT), was retained in the cytosol (Fig. 5, Table 2). To examine
whether expression of these Bax constructs would induce apoptosis, we constitutively coexpressed WT Bax or the deletion mutants along with GFP in a Bax deficient cell line (Bax

-/-

HCT116) [51]. As shown in Figure 6, like Bax-ΔNT, expression of WT Bax induced apoptosis
-/-

+

in Bax HCT116 cells, as evidenced by the loss of GFP cells, whereas Bax-ΔCT remained
+

cytosolic and did not induce apoptosis, as evidences by the presence of GFP cells. These results
show that an intact C-terminus of Bax causes apoptosis, while the N-terminus promotes cytosolic
retention.
Substitution of Lys189 and/or Lys190 with negatively charged residues, Asp or Glu,
resulted in the cytosolic retention of Bax (Bax-DD, Bax-EE, and Bax-EK) in 293 cells, and no
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-/-

apoptosis was observed in BAX HCT116 cells (Table 2, Figs. 5 and 6). Whereas, substitution
of Lys189 and/or Lys190 with another positively charged residue, Arg (Bax-RR) led to
mitochondrial localization and apoptosis (Table 2, Figs. 5 and 6). Substitution of Lys 189 and
Lys190 with a polar amino acid, like Gln (Bax-QQ), led to more Bax in the cytosol and less cell
death, when compared WTBax and Bax-RR, but more mitochondrial Bax and cell death was
observed when compared to Bax-ΔCT and Bax-EE (Table 2, Figs. 5and 6). Substitution of
Lys189 and/or Lys190 with the hydrophobic residue leucine (Bax-LL) resulted in mitochondrial
binding and apoptosis (Figs. 5 and 6, Table 2). Loss of Lys189 (Bax-EK) also rendered Bax to
be mainly cytosolic, which was not observed by loss of Lys190 (Bax-KMGK) (Figs. 5 and 6,
Table 2).

These data suggest that Lys 189/190 was essential for both Bax binding to

mitochondria and its apoptotic activity.
The C- terminus Lys 189/190 of Bax is involved in Bax binding to mitochondria
To determine whether the C-terminus Lys 189/190 is critical for Bax binding to
mitochondria, we attached the C-terminal α9 helix of Bax (CT) (amino acids 168-192) to EGFP
(EGFP-CT) and examined the subcellular localization in Bax-/- HCT-116 cells. Moreover, mutant
C-terminal constructs, CT-EE and CT-LL, were also attached EGFP for evaluation.
constructs were constitutively expressed in Bax-/- HCT-116 cells.

The

After 24 hours, Bax C-

terminal tagged EGFP was assayed by immunoblotting with an anti-EGFP antibody in both
mitochondrial and cytosolic lysates. As shown in Figure 7, a heavy band of EGFP was observed
in cytosolic lysates but not in mitochondrial lysates. Both EGFP-CT-WT) and EGFP-CT-LL
expression displayed translocation from cytosol to mitochondria, as evidenced by the increased
aggregates of EGFP in the mitochondrial extracts. EGFP-CT-EE was located in the cytosolic but
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not in the mitochondrial fractions, as evidenced by the decreased aggregates of EGFP in the
mitochondrial extracts. These data further confirmed that Lys 189/190 in the C-terminal of Bax
are involved in Bax binding to mitochondria.
The C- terminus Lys 189/190 of Bax is critical for Bax apoptotic activity
Since Lys 189/190 mutants displayed different intracellular localization (Fig. 7), we
determined whether these mutants altered the apoptotic process in the presence and absence of
endogenous Bax using Bax+/+ HCT-116 and Bax-/- HCT-116 cells. Apoptosis was detected by
live cell imaging to examine any morphological changes over time after transfection with EGFPtagged Bax C-terminal and its mutants. As shown in Figure 8, expression of EGFP-CT-WT in
Bax+/+ HCT-116 cells quickly caused apoptotic cell death, whereas expression of both EGFPCT-EE and EGFP-CT-LL did not induce apoptosis within the same time period. However,
expression of EGFP-CT-WT in Bax-/- HCT-116 cell, or either EGFP-tagged CT-EE, or LL
mutants, did not cause cell death within the same time period. These results suggest that Lys
189/190 is crucial for Bax apoptotic activity and also indicates that the apoptotic activity of
EGFP-tagged CT-WT might be correlated and depend upon the levels of endogenous Bax.
Expression of the C-terminal α9 helix of Bax induces the translocation of Bax to
mitochondria
To further determine whether expression of the C-terminal α9 helix of Bax induces the
translocation of Bax to mitochondria, we examined the effects of induction of DD-tagged fulllength Bax (DD-FL-Bax) and DD-tagged C-terminal α9 helix (amino acids 173-192) (DD-CTBax) WT and EE, LL, RR mutations. Mitochondrial translocation of the DD-CT Bax constructs
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was examined in HCT-116 cells. To induce expression, Shield 1 was added for after to cells that
had been transfected with constructs for 24 hours. Induction time was 4 hours. Both the cytosolic
and mitochondrial proteins were isolated from non-apoptotic HCT116 cells, and the expression
of DD-tagged Bax peptides and endogenous Bax were determined by immunoblots with either
anti-DD or anti-Bax antibodies. As shown in Figure 9, most of DD-tagged full-length Bax was
found in cytosolic extracts, and a substantial fraction of DD-FL-Bax was also found in
mitochondria extracts. Expression of DD-CT-WT Bax peptides or DD-tagged mutant peptides
(EE, LL and RR) was observed all in the mitochondrial extracts; only DD-tagged LL was found
a very faint band in the cytosolic extracts. More interestingly, expression of DD-tagged Cterminal Bax activated endogenous Bax, which was observed by translocation into mitochondria.
These results were further confirmed by immunofluorescence, double-staining with anti-DD and
anti-HSP60 (mitochondrial content) antibodies (Fig.10A).

Expression of DD-CT-WT and

mutants (EE, LL and RR) localized to mitochondria as evidenced by double-positive staining.
There was no significant difference in the co-localization of DD-tagged peptides to mitochondria
between Bax+/+ and Bax-/- HCT-116 cells (Fig.10B). These data suggest that expression of Cterminal α9 helix of Bax alone can bind to mitochondria.
Expression of the C-terminal α9 helix of Bax induces apoptotic cell death
To determine whether the C-terminal α9 helix of Bax could mimic the apoptotic activity
of the full-length Bax, expression of DD-tagged Bax-FL, the C-terminal α9 helix of Bax and its
mutant peptides was induced in Bax+/+ and Bax-/- HCT-116 cells as described in Methods. Cells
were transfected for 24 hours. To image mitochondria, the cells were incubated 30 minutes with
1nM MitoTracker Red 580. Cells were imaged before adding shield 1 and 5 hours after adding
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shield 1. As shown in Figure 11, expression of DD-CT-WT caused apoptotic cell death in both
Bax+/+ HCT-116 and Bax-/- HCT-116 cells within 5 hours. However, expression of DD-tagged
CT mutant peptides, like EE and LL, RR did not cause apoptosis in either Bax+/+ and Bax-/- HCT116 cells within the same time period. The apoptotic activity of DD-tagged CT-WT was further
examined by flow cytometry analysis. Representative cytometric analytical data are shown in
Figure 11 and Table 3. Cells were examined 24 hours after addition shield 1. Parameters
assessed were early apoptotic indicators (DNA fragmentation and membrane instability). From
previous data (Figure 11), cells expressing high levels of DD-tagged WT peptide died within 5
hours after induction in Bax+/+ cells. Whereas 24 hours after induction, cells, mostly expressing
low levels of DD-tagged CT-WT peptide, showed less DNA fragmentation and membrane
destabilization. Cells expressing heterogeneous levels of DD-tagged EE showed less DNA
fragmentation and membrane instability. Cells expressing DD-tagged LL showed increased
DNA fragmentation but less membrane destabilization. Cells expressing heterogeneous levels of
DD-tagged RR showed both increased DNA fragmentation and membrane destabilization.
These data suggest that DD-tagged CT-WT has significant cell toxicity and kills cells quickly,
while DD-tagged RR has the potential to kill cells but may take longer. DD-tagged LL and EE
displayed the least cell toxicity. These results showed the possible cytotoxic effects of Bax
binding to mitochondria, as evidenced by immunoblots shown in Figure 9. Taken together, these
data suggest that the C-terminal α9 helix of Bax may activate endogenous Bax, thereby
enhancing Bax apoptotic activity in Bax+/+ HCT-116 cells, and that Lys 189/190 is instrumental
for the apoptotic activity of the C-terminal α9 helix of Bax.
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Expression of the C-terminal of Bax on ATP production in HCT-116 cells
Since we had shown that expression of the full-length Bax can restore ATP production in
Bax-/- HCT-116 cells, we examined whether the C-terminal α9 helix of Bax could mimic the
activity of the full-length Bax on ATP production. After transfection of DD-tagged C-terminal
α9 helix of Bax constructs for 24 hours, expression of DD-CT-WT of Bax peptides was induced
by shield 1 for 0, 2, 4, 6, and 8 hours in Bax+/+ and Bax-/- HCT-116 cells. The intracellular ATP
production was examined as described in the Methods in Chapter 2. As shown in Figure 13, the
basal levels of ATP in non-transfected Bax+/+ controls is higher than that in the Bax-/- controls.
Expression of the DD-tagged C-terminal α9 helix of Bax (WT or mutants) had no significant
effects on ATP production in both Bax+/+ HCT-116 cells and Bax-/- HCT-116 cells. These
results suggest that the C-terminal α9 helix of Bax may be not involved in the regulation of
mitochondrial bioenergetics in non-apoptotic cells.
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Figure 5. Mutation of Lys 189/190 at C-terminal of Bax alters intracellular localization.
Mitochondrial translocation of HA-tagged Bax mutants was examined by western blot. Bax was
inducibly expressed in 293 cells using the Flp-In T-Rex expression system. After 24 hours of
induction with tetracycline, cells were lysed and mitochondrial and cytosolic lysates prepared.
Expression of induced HA-tagged Bax was assayed by immunoblotting with an anti-HA
antibody. As controls for loading and subcellular fractionation, p38 MAPK was blotted for
cytosolic content and Prohibitin was blotted for mitochondrial content. HA-tagged Bax-KK
indicates HA-tagged Bax wild type. Data are representative of five independent assays.
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Figure 6. Mutation of Lys 189/190 at C-terminus of Bax alters apoptotic activity of Bax.
Apoptosis was assessed by loss of EGFP expressing cells. HA-tagged Bax mutants were
-/transiently co-expressed with EGFP in Bax HCT116 cells. After 48 hours, HCT116 cells were
microscopically observed for loss of EGFP+ cells. Images were obtained using a Nikon Eclipse
E1000 microscope 10X objective with a SPOT RT camera.
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cytosol

mitochondria

Figure 7. EGFP tagged C- terminus Lys 189/190 mutation of Bax alters intracellular localization.
Mitochondrial translocation of EGFP-tagged Bax C-terminus mutants was examined by western
blot. Bax was inducibly expressed in Bax-/-HCT116 cells using the Flp-In T-Rex expression
system. After 24 hours of induction with tetracycline, cells were lysed and mitochondrial and
cytosolic lysates prepared. Induced EGFP-tagged Bax peptides were probed with an anti-GFP
antibody. GFP-KK indicates EGFP-tagged wild type Bax. Data are representative of five
independent assays.
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Figure 8. GFP tagged C-terminal peptide of Bax, but not mutant peptides, induced cell death in
HCT-116 cells.
Cells were transfected with the GFP-tagged C-terminal wild type (KK), EE and LL mutants of
Bax constructs into both Bax+/+ and Bax-/- HCT116 cells using the TransIT-LT1 transfection
reagent (Mirus) according to the manufacturer’s protocol. Time-lapse movies were made by the
UltraView spinning disc confocal system with AxioObserver.Z1 stand, and a Plan-Apochromat
63x Oil objective.
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Figure 9. Intracellular localization of DD-tagged full-length and DD-tagged C-terminus Lys
189/190 mutants.
The intracellular localization of DD-tagged Bax full-length (FL-Bax) and C-terminus mutants
was examined by western blot. Bax was inducibly expressed in Bax+/+HCT-116 cells by adding
the ligand Shield 1. After 4 hours of induction, cells were lysed and mitochondrial and cytosolic
lysates were extracted. Expression of induced DD-tagged Bax peptides was assayed by
immunoblotting with an anti-DD antibody. Endogenous Bax were probed with anti-Bax
antibody. p38 MAPK and prohibitin were probed as loading controls for cytosolic and
mitochondrial content, respectively. Data are representative of two independent assays.
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Figure 10. Detection of intracellular localization of DD-tagged C-terminus Lys 189/190 mutants
by immunofluorescent staining.
Bax+/+ and Bax-/- HCT-116 cells were cultured for 24 hours. The DD-tagged Bax C-terminal WT
peptide and DD-tagged Bax C-terminal EE, LL, RR mutants constructs were transfected into the
cells for 24 hours, followed by treatment with shield 1 for 4 hours. Cells were fixed and doublestained with primary antibodies for HSP60 and DD, followed by incubated with secondary antirabbit-Cy3 and anti-mouse-Texas red as described in methods. Representative images are shown
in (A). The bar graphs (B) indicated the quantitative assay of colocalization of DD-tagged
peptides to mitochondria. The measurements are represented by three samples. Statistical
analysis was performed with ANOVA and there is no statistically significant difference.
(contributed by R. Boohaker)
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Figure 11. Expression of DD-tagged Bax C-terminal peptides induced cell death in HCT-116
cells.
DD-tagged C-terminal wild type (KK) and EE, LL, RR mutants of Bax were transfected into
both Bax+/+ and Bax-/- HCT-116 cells using the TransIT-LT1 transfection reagent at described in
the methods. After adding shield 1 to induce the Bax peptide expression, the time-lapse movies
were acquired with the UltraView spinning disc confocal system over 5 hours. Snapshots were
taken at indicated time points. Data are representative of four independent images.
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Figure 12. Detection of cell death by flow cytometry.
DD-tagged Bax C- terminus wild type (DD-CT-KK) ant its mutants (DD-CT-EE, DD-CT-LL
and DD-CT-RR) were transfected into the Bax+/+ HCT-116 cells using the TransIT-LT1
transfection reagent at described in the Methods. After induction with shield 1 for 24 hours, cells
(1x106) were harvested and stained with F2N12S and SYTOX® AADvanced™ solutions as
described in methods. Samples were analyzed on BD FACSAria II flow cytometer. Data are
representative of two independent assays.
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Figure 13. Expression of C-terminal Bax on ATP production in Bax+/+and Bax-/- HCT-116 cells.
Bax+/+ and Bax-/- HCT-116 cells were transiently transfected with DD-tagged Bax-CT-WT for 24
hrs, then cells were treated with shield 1 for 0, 2, 4, 6, 8 hours. Changes in ATP levels were
measured as described in methods. There was no statistically significant difference in ATP
levels at each time points.
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Table 1. Lists of primer pairs
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Table 2. Lys189/190 mutations on Bax intracellular localization
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Table 3. Effects of DD-tagged Bax-CT and its mutants on cell vability
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Discussion

As an important pro-apoptotic protein, Bax is involved in the pathology of a number of
diseases and is increasingly considered as a potential therapeutic target. Abounding evidence has
demonstrated that translocation of Bax to the mitochondria, permeabilization of the
mitochondrial outer membrane and release of cytochrome c are key events in apoptosis [1-3].
Bax is a member of the BCL-2 family of apoptotic modulators that exists either in a soluble
cytoplasmic form or a membrane-bound form. Today, growing evidence indicates that upon
apoptotic stimuli, Bax undergoes a conformational change, exposing its C-terminal α9 helix, and
translocates to mitochondria, leading to apoptosis [8, 18-20]. It is unknown, however, whether
the α9 helix of Bax is a membrane binding domain or a regulatory domain. In our previous
computational mutagenesis studies, we predicted that Lys 189/190 at the C-terminal α9 helix of
Bax may play a critical role in the regulation of mitochondrial membrane binding activity of Bax
in response to apoptotic stimuli (Khaled A, unpublished data). In the present study, using a
mutagenesis strategy we identified that positively charged lysines 189/190, located at the distal
end of the C-terminal α9 helix of Bax, are critical for the apoptotic activity of Bax, and these two
lysines might define how Bax interacts with mitochondrial membranes.

We showed that

expression of full-length Bax (Bax-FL) led to mitochondrial translocation and apoptosis, whereas
deletion of the C-terminal α9 helix resulted in cytosolic retention and no apoptosis. Mutation of
the two lysine residues changed how Bax bound to mitochondrial membranes. We replicated the
results achieved with full-length Bax by attaching the α9 helix of Bax to EGFP or to a regulatory
element, a degradation domain (DD), and induced apoptosis upon expression in cells, whereas
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these effects were impaired by mutation of Lys 189/190. These results indicated that the two
lysines in the α9 helix are critical for the apoptotic activity of Bax.
Bax translocation from the cytosol to the mitochondria is a critical event of apoptosis.
Currently, Bax activation by direct interaction with BH3-proteins has been suggested [50].
However, this working model cannot explain how Bax moves to mitochondria in cells from mice
deficient in BIM, BAD or PUMA, suggesting that translocation of Bax can occur independently
of such BH3-only proteins [53]. Thus, it was recently suggested that the conformational change
of Bax occurs in the cytosol leading to release of the C-terminal α9 helix from the hydrophobic
grove, thereby exposing the previously hidden BH3 domain and then Bax anchors into the OMM
through its N-terminus [14] or its C-terminus [19]. Our recent studies showed that the increase
in intercellular pH could induce a conformation change in Bax, resulting in the C-terminal being
exposed, leading to Bax mitochondria translocation [21]. In non-apoptotic cells, the C-terminal
helix 9 occupies the hydrophobic groove of Bax. It is possible that the conformational change
that occurs upon an apoptotic stimulus may expose the membrane binding domains, since the Cterminus has been proposed to mediate the mitochondrial insertion of Bax. In contrast, studies
demonstrated that the N-terminal α1 helix domain, not the C-terminal, is essential for Bax
insertion and function [14, 22, 54]. To understanding the role of the C-terminal of Bax, mutation
of the C-terminal (Bax-ΔCT) was performed and we found that expression of Bax-ΔCT retained
Bax in the cytosol and abolished apoptosis in Bax-/- HCT-116 cells. However, mutation of the
N-terminal (Bax-ΔNT) caused Bax to move to mitochondria and cell death. These data suggest
that the α9 helix plays an essential role in the translocation of Bax to mitochondria. The crucial
role of α9 helix was investigated by analyzing different substitutions at Lys 189/190, the positive
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charged residues in α9 helix. Data presented here clearly demonstrated that the C-terminal α9
helix can mediate insertion of Bax into mitochondria. We also identified Lys 189/190 as critical
for the apoptotic activity of Bax. We replicated the results achieved with full-length Bax by
attaching the α9 helix of Bax to EGFP or to a regulatory element, a degradation domain (DD),
and induced the translocation of Bax to mitochondria and induced apoptosis upon expression in
cells.

Our conclusions are based on results derived from computational structural studies,

targeted mutagenesis studies, and analysis through live cell imaging, flow cytometry, and
immunoblotting.
Work done by others have shown that the modification of C-terminal residues by
phosphorylation could be a means to regulate the mitochondrial translocation of Bax. For
example mutation of serine 184 in the full length protein [56] or a C-terminal peptide [57] altered
the localization and membrane-binding functions of Bax protein or peptide. Substitution of
Ser184 with Asp, Gln or Lys leads to a protein exclusively cytosolic, whereas the deletion of
Ser184 or substitution with Val or Ala causes to a protein exclusively localized to the
mitochondria [58]. Mutation of threonine likewise did the same [55], suggesting that the Cterminus of Bax was a regulatory domain.

We found that mutation of the two lysines

significantly affected the apoptotic activity of the C-terminal of Bax. Mutation of these two
lysines altered Bax intracellular localization. Expression of the C-terminal Bax mutants may
activate the endogenous Bax by moving it to mitochondria. Recently, it was reported that the
Bax C-terminus was essential for Bax translocation to mitochondria but was not the only binding
signal [59]. Therefore, it will be interesting to examine how the C-terminal mutants affect the
intracellular localization of endogenous Bax.
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In summary, our results suggest that the C-terminal α9 helix of Bax serves as a
mitochondrial membrane binding domain and that Lys 189/190 are critical for the apoptotic
activity of Bax. This study also suggests that expression of the C-terminal α9 helix is sufficient
to induce apoptotic cell death, indicating the C-terminal α9 helix may be developed as a novel
agent for cytotoxic therapy.
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CHAPTER 4: CONCLUSIONS

Apoptosis is essential for tissue development and homeostasis, and is involved in many
disease pathologies. The Bcl-2 family of proteins is a major regulator of apoptosis and includes
both pro- and anti-apoptotic proteins. The balance between these proteins defines whether a cell
will live or die. Bax is a well-known pro-apoptotic Bcl-2 family protein which participates in the
induction of apoptosis in response to a variety of apoptotic signals. Mostly Bax resides in the
cytoplasm of non-apoptotic cells, and a minor fraction of Bax is associated with the
mitochondrial membrane.

Multiple mechanisms have been suggested to explain how Bax

induces apoptosis. The translocation of Bax to mitochondria is considered as a principal trigger
of apoptosis, although how Bax translocates to mitochondria remains unclear. Recently, it has
been shown that Bax can affect mitochondrial reactive oxygen species (ROS) production in nonapoptotic neurons, suggesting that Bax localizes to and uses mitochondria as its major site of
action, and has dual function in regulation of cell fate.
The results presented here demonstrate that Bax has a dual property of action: (1)
regulation of mitochondrial bioenergetics in non-apoptotic cells, and (2) triggering apoptosis by
translocation to mitochondria via its C-terminal α9 helix. Our results, however, suggest that the
C-terminal α9 helix domain is not involve in or regulates mitochondrial bioenergetics, and that
the Lys189/190 at the C-terminal α9 helix is the structural element responsible for the
mitochondrial membrane binding activity of Bax. We further demonstrate that the C-terminal α9
helix can mimic the function of the full-length Bax, binding to mitochondrial membranes and
inducing apoptosis. These results suggest two possible mechanisms to explain the apoptotic
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activity of the C-terminal peptides. One mechanism could be that the peptides directly bind to
mitochondria, disrupt the membrane and cause the release of cytochrome C. Alternatively, the
C-terminal peptides could bind to and activate cytoplasmic Bax, which translocates to the
mitochondria and causes the release of cytochrome C. Thus, development of a novel agent based
on the C-terminal of Bax may overcome resistance to cancer chemotherapy and could be used as
therapeutic strategy for treatment of cancer. On the other hand, Bax C-terminal mutate peptides
(like Bax-CT-EE) may counteract apoptosis and protect cells from damage that leads to
neurodegeneration and cardiovascular diseases.
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